Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.

In this study, 27.9% of Parkinson's disease patients reported hair loss, with a higher incidence linked to a daily levodopa-equivalent dose over 448 mg, suggesting an association between dopaminergic medication use and hair loss complaints.

This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.

This study found that local injections of fetal tissue mesenchymal stromal cells in mice significantly improved healing and hair follicle density after high-dose radiation-induced skin damage.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

In this pilot randomized clinical trial, TRT combined with finasteride increased lean mass, muscle size, and bone mineral density without prostate enlargement in men with spinal cord injury, suggesting potential benefits for body composition and musculoskeletal health.

In this study, researchers investigated factors predicting resistance to clomiphene citrate in women with anovulatory PCOS, identifying AMH and SHBG levels as significant indicators, but they found no reliable thresholds for predicting resistance to the standard 50 mg/day dose.

This study observed a slight reduction in blood pressure in normotensive patients after taking a 5-mg dose of oral minoxidil, particularly within the first two hours and more so in those with high baseline blood pressure.

This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.

This review reports that platelet-rich plasma may be more effective for musculoskeletal conditions when prepared with high platelet doses and low leukocyte content, but further trials are needed to confirm optimal formulations.

This study found that intradermal injections of platelet-rich plasma were equally safe and effective for treating androgenetic alopecia, with higher platelet numbers possibly enhancing hair density and follicle diameter.

This systematic review and meta-analysis found that low-dose minoxidil treatment effectively enhances facial hair development with relatively minimal side effects, which can be beneficial in primary care settings.

This review discusses unconventional therapies for managing alopecia areata, highlighting antihistamines, cryotherapy, and low-dose naltrexone, but reports no new clinical results and emphasizes the need for further research.

In this case report, a 16-year-old female with Netherton syndrome, a rare genetic disorder, exhibited symptoms such as skin issues, hair abnormalities, and elevated serum IgE levels. The diagnosis was supported by skin biopsy, and treatment included topical therapies, NB-UVB, and infliximab.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This case report details a 23-year-old woman who was poisoned with thallium by a colleague and treated with activated charcoal and Prussian blue.

Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.

Scalp cooling prevented hair loss in half of the patients, despite significant side effects.

This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.

In this study, researchers observed a dose-dependent occurrence of persistent radiation-induced alopecia in patients with primary CNS tumors or head and neck sarcomas, noting distinctive patterns and features, and suggesting potential benefits of topical minoxidil and procedural interventions for treatment.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

Radiation therapy with a higher dose for the brain improves survival in cerebellar medulloblastoma.

This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.

This study found that high-dose cyproterone acetate was effective for treating hirsutism, but 33% of patients felt their condition worsened on low-dose maintenance therapy, despite no significant change in objective measures of hair growth.

Taking a small dose of prednisone before menstruation can almost completely prevent premenstrual acne with few side effects.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

This study supports the conclusion that the hormetic dose-response model is the most prevalent and fundamental model in biological and biomedical sciences, applicable to a wide range of clinical conditions.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This case study reports that low-dose testosterone therapy improved libido and sexual functions in a 36-year-old fragile X carrier female with hypoactive sexual desire disorder when monitored regularly for lab parameters.